Zensar Technologies Limited disclosed a board-approved merger plan pursuant to Regulation 30(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board of Directors meeting held on July 29, 2026 (commencing at 05:00 PM IST and concluding at 08:05 PM IST) accorded in-principle approval for the merger of two US-based step-down subsidiaries:

  • Bridgeview Life Sciences LLC
  • M3BI LLC

These entities will be merged into Zensar Technologies Inc., USA, a material wholly owned subsidiary of the company, either directly or through the establishment of a new entity to facilitate the merger.

Financial Details of Entities (as of March 31, 2026, standalone basis)

| Entity Name | Net Worth (USD Million) | Turnover (USD Million) |

| Bridgeview Life Sciences LLC | 0.4 | 4.74 |

| M3BI LLC | 9.32 | 46.8 |

| Zensar Technologies Inc. | 74.66 | 326.96 |

Transaction Details

  • Related Party Transaction: No, the transaction does not fall under related party transactions. As per Regulation 23(5)(b) of SEBI Listing Regulations, related party transaction provisions are not applicable to this merger.
  • Business Area: All entities are engaged in providing digital solutions and technology services to global organizations.
  • Rationale: The merger aims to achieve greater operational efficiencies, business synergies, higher business synergies, and effective management through unified control of operations.
  • Consideration: Not applicable as the merger is between step-down subsidiaries of Zensar Technologies Limited.
  • Shareholding Impact: There will be no change in the shareholding pattern of Zensar Technologies Limited.

Next Steps

The Board/Shareholders of the respective merging entities (Bridgeview Life Sciences LLC and M3BI LLC) as well as Zensar Technologies Inc., USA will consider the merger proposal separately.

Outcome

Consequent to the merger, the merging entities (Bridgeview Life Sciences LLC and M3BI LLC) will cease to exist as step-down subsidiaries of the company.

The disclosure was signed by Anand Champalal Daga and submitted to both BSE Limited and National Stock Exchange of India Limited.